Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.
Identifieur interne : 004543 ( Main/Exploration ); précédent : 004542; suivant : 004544Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.
Auteurs : Satoshi Saito [Japon] ; Satoshi Ota ; Hideyuki Seshimo ; Yuichiro Yamazaki ; Setsuo Nomura ; Toshihiro Ito ; Jun Miki ; Masao Ota ; Hirofumi Fukushima ; Hiroo MaedaSource :
- Transfusion [ 0041-1132 ] ; 2002.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte d'âge moyen (MeSH), Alloanticorps (sang), Antigènes HLA-C (analyse), Antigènes HLA-C (immunologie), Enfant d'âge préscolaire (MeSH), Femelle (MeSH), Histocompatibilité (MeSH), Humains (MeSH), Incompatibilité sanguine (MeSH), Mâle (MeSH), Numération des plaquettes (MeSH), Plaquettes (immunologie), Résultat thérapeutique (MeSH), Transfusion de plaquettes (MeSH), Tumeurs hématologiques (sang), Tumeurs hématologiques (thérapie).
- MESH :
- analyse : Antigènes HLA-C.
- immunologie : Antigènes HLA-C, Plaquettes.
- sang : Alloanticorps, Tumeurs hématologiques.
- thérapie : Tumeurs hématologiques.
- Adolescent, Adulte d'âge moyen, Enfant d'âge préscolaire, Femelle, Histocompatibilité, Humains, Incompatibilité sanguine, Mâle, Numération des plaquettes, Résultat thérapeutique, Transfusion de plaquettes.
English descriptors
- KwdEn :
- Adolescent (MeSH), Blood Group Incompatibility (MeSH), Blood Platelets (immunology), Child, Preschool (MeSH), Female (MeSH), HLA-C Antigens (analysis), HLA-C Antigens (immunology), Hematologic Neoplasms (blood), Hematologic Neoplasms (therapy), Histocompatibility (MeSH), Humans (MeSH), Isoantibodies (blood), Male (MeSH), Middle Aged (MeSH), Platelet Count (MeSH), Platelet Transfusion (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , analysis : HLA-C Antigens.
- blood : Hematologic Neoplasms, Isoantibodies.
- immunology : Blood Platelets, HLA-C Antigens.
- therapy : Hematologic Neoplasms.
- Adolescent, Blood Group Incompatibility, Child, Preschool, Female, Histocompatibility, Humans, Male, Middle Aged, Platelet Count, Platelet Transfusion, Treatment Outcome.
Abstract
BACKGROUND
HLA-C antigens have been thought to be of little significance in determining the efficacy of platelet transfusions. However, six alloimmunized patients were encountered who were refractory to platelet transfusions because of anti-HLA-Cw3, -Cw3, -Cw7, or -Cw8.
STUDY DESIGN AND METHODS
Between 1995 and the present, 88 patients with hematologic malignancies became refractory to random-donor platelet transfusions due to HLA antibodies. HLA-A- and HLA-B-compatible platelet transfusions were successful in boosting platelet levels with 82 of the patients. This study concerns the remaining six HLA-immunized patients who were refractory to HLA-A- and HLA-B-compatible platelet transfusions. The response to the platelet transfusions was assessed by calculating both 1- and 24-hour posttransfusion CCIs for each transfusion.
RESULTS
The average CCI(1 hour) and CCI(24 hours) in all patients were 20.0 and 12.8 for HLA-A-, HLA-B-, and HLA-C-compatible transfusions and were 1.4 and 1.2 for HLA-A- and HLA-B-compatible but HLA-C-incompatible transfusions, respectively (p < 0.001).
CONCLUSION
These findings clearly indicate that matching of the HLA-C antigens is also required in some alloimmunized patients to obtain the effectiveness of platelet transfusions.
DOI: 10.1046/j.1537-2995.2002.00051.x
PubMed: 11961234
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.</title><author><name sortKey="Saito, Satoshi" sort="Saito, Satoshi" uniqKey="Saito S" first="Satoshi" last="Saito">Satoshi Saito</name><affiliation wicri:level="1"><nlm:affiliation>Tissue Typing Laboratory, Nagano Red Cross Blood Center, Japan. stsaito@poplar.ocn.ne.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Tissue Typing Laboratory, Nagano Red Cross Blood Center</wicri:regionArea><wicri:noRegion>Nagano Red Cross Blood Center</wicri:noRegion></affiliation></author><author><name sortKey="Ota, Satoshi" sort="Ota, Satoshi" uniqKey="Ota S" first="Satoshi" last="Ota">Satoshi Ota</name></author><author><name sortKey="Seshimo, Hideyuki" sort="Seshimo, Hideyuki" uniqKey="Seshimo H" first="Hideyuki" last="Seshimo">Hideyuki Seshimo</name></author><author><name sortKey="Yamazaki, Yuichiro" sort="Yamazaki, Yuichiro" uniqKey="Yamazaki Y" first="Yuichiro" last="Yamazaki">Yuichiro Yamazaki</name></author><author><name sortKey="Nomura, Setsuo" sort="Nomura, Setsuo" uniqKey="Nomura S" first="Setsuo" last="Nomura">Setsuo Nomura</name></author><author><name sortKey="Ito, Toshihiro" sort="Ito, Toshihiro" uniqKey="Ito T" first="Toshihiro" last="Ito">Toshihiro Ito</name></author><author><name sortKey="Miki, Jun" sort="Miki, Jun" uniqKey="Miki J" first="Jun" last="Miki">Jun Miki</name></author><author><name sortKey="Ota, Masao" sort="Ota, Masao" uniqKey="Ota M" first="Masao" last="Ota">Masao Ota</name></author><author><name sortKey="Fukushima, Hirofumi" sort="Fukushima, Hirofumi" uniqKey="Fukushima H" first="Hirofumi" last="Fukushima">Hirofumi Fukushima</name></author><author><name sortKey="Maeda, Hiroo" sort="Maeda, Hiroo" uniqKey="Maeda H" first="Hiroo" last="Maeda">Hiroo Maeda</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:11961234</idno><idno type="pmid">11961234</idno><idno type="doi">10.1046/j.1537-2995.2002.00051.x</idno><idno type="wicri:Area/Main/Corpus">004661</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">004661</idno><idno type="wicri:Area/Main/Curation">004661</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">004661</idno><idno type="wicri:Area/Main/Exploration">004661</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.</title><author><name sortKey="Saito, Satoshi" sort="Saito, Satoshi" uniqKey="Saito S" first="Satoshi" last="Saito">Satoshi Saito</name><affiliation wicri:level="1"><nlm:affiliation>Tissue Typing Laboratory, Nagano Red Cross Blood Center, Japan. stsaito@poplar.ocn.ne.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Tissue Typing Laboratory, Nagano Red Cross Blood Center</wicri:regionArea><wicri:noRegion>Nagano Red Cross Blood Center</wicri:noRegion></affiliation></author><author><name sortKey="Ota, Satoshi" sort="Ota, Satoshi" uniqKey="Ota S" first="Satoshi" last="Ota">Satoshi Ota</name></author><author><name sortKey="Seshimo, Hideyuki" sort="Seshimo, Hideyuki" uniqKey="Seshimo H" first="Hideyuki" last="Seshimo">Hideyuki Seshimo</name></author><author><name sortKey="Yamazaki, Yuichiro" sort="Yamazaki, Yuichiro" uniqKey="Yamazaki Y" first="Yuichiro" last="Yamazaki">Yuichiro Yamazaki</name></author><author><name sortKey="Nomura, Setsuo" sort="Nomura, Setsuo" uniqKey="Nomura S" first="Setsuo" last="Nomura">Setsuo Nomura</name></author><author><name sortKey="Ito, Toshihiro" sort="Ito, Toshihiro" uniqKey="Ito T" first="Toshihiro" last="Ito">Toshihiro Ito</name></author><author><name sortKey="Miki, Jun" sort="Miki, Jun" uniqKey="Miki J" first="Jun" last="Miki">Jun Miki</name></author><author><name sortKey="Ota, Masao" sort="Ota, Masao" uniqKey="Ota M" first="Masao" last="Ota">Masao Ota</name></author><author><name sortKey="Fukushima, Hirofumi" sort="Fukushima, Hirofumi" uniqKey="Fukushima H" first="Hirofumi" last="Fukushima">Hirofumi Fukushima</name></author><author><name sortKey="Maeda, Hiroo" sort="Maeda, Hiroo" uniqKey="Maeda H" first="Hiroo" last="Maeda">Hiroo Maeda</name></author></analytic><series><title level="j">Transfusion</title><idno type="ISSN">0041-1132</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Blood Group Incompatibility (MeSH)</term><term>Blood Platelets (immunology)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>HLA-C Antigens (analysis)</term><term>HLA-C Antigens (immunology)</term><term>Hematologic Neoplasms (blood)</term><term>Hematologic Neoplasms (therapy)</term><term>Histocompatibility (MeSH)</term><term>Humans (MeSH)</term><term>Isoantibodies (blood)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Platelet Count (MeSH)</term><term>Platelet Transfusion (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Alloanticorps (sang)</term><term>Antigènes HLA-C (analyse)</term><term>Antigènes HLA-C (immunologie)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Femelle (MeSH)</term><term>Histocompatibilité (MeSH)</term><term>Humains (MeSH)</term><term>Incompatibilité sanguine (MeSH)</term><term>Mâle (MeSH)</term><term>Numération des plaquettes (MeSH)</term><term>Plaquettes (immunologie)</term><term>Résultat thérapeutique (MeSH)</term><term>Transfusion de plaquettes (MeSH)</term><term>Tumeurs hématologiques (sang)</term><term>Tumeurs hématologiques (thérapie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>HLA-C Antigens</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Antigènes HLA-C</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hematologic Neoplasms</term><term>Isoantibodies</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes HLA-C</term><term>Plaquettes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Blood Platelets</term><term>HLA-C Antigens</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Alloanticorps</term><term>Tumeurs hématologiques</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hematologic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs hématologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Blood Group Incompatibility</term><term>Child, Preschool</term><term>Female</term><term>Histocompatibility</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Platelet Count</term><term>Platelet Transfusion</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte d'âge moyen</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Histocompatibilité</term><term>Humains</term><term>Incompatibilité sanguine</term><term>Mâle</term><term>Numération des plaquettes</term><term>Résultat thérapeutique</term><term>Transfusion de plaquettes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>HLA-C antigens have been thought to be of little significance in determining the efficacy of platelet transfusions. However, six alloimmunized patients were encountered who were refractory to platelet transfusions because of anti-HLA-Cw3, -Cw3, -Cw7, or -Cw8.</p></div><div type="abstract" xml:lang="en"><p><b>STUDY DESIGN AND METHODS</b></p><p>Between 1995 and the present, 88 patients with hematologic malignancies became refractory to random-donor platelet transfusions due to HLA antibodies. HLA-A- and HLA-B-compatible platelet transfusions were successful in boosting platelet levels with 82 of the patients. This study concerns the remaining six HLA-immunized patients who were refractory to HLA-A- and HLA-B-compatible platelet transfusions. The response to the platelet transfusions was assessed by calculating both 1- and 24-hour posttransfusion CCIs for each transfusion.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The average CCI(1 hour) and CCI(24 hours) in all patients were 20.0 and 12.8 for HLA-A-, HLA-B-, and HLA-C-compatible transfusions and were 1.4 and 1.2 for HLA-A- and HLA-B-compatible but HLA-C-incompatible transfusions, respectively (p < 0.001).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These findings clearly indicate that matching of the HLA-C antigens is also required in some alloimmunized patients to obtain the effectiveness of platelet transfusions.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11961234</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0041-1132</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Transfusion</Title><ISOAbbreviation>Transfusion</ISOAbbreviation></Journal><ArticleTitle>Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.</ArticleTitle><Pagination><MedlinePgn>302-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">HLA-C antigens have been thought to be of little significance in determining the efficacy of platelet transfusions. However, six alloimmunized patients were encountered who were refractory to platelet transfusions because of anti-HLA-Cw3, -Cw3, -Cw7, or -Cw8.</AbstractText><AbstractText Label="STUDY DESIGN AND METHODS" NlmCategory="METHODS">Between 1995 and the present, 88 patients with hematologic malignancies became refractory to random-donor platelet transfusions due to HLA antibodies. HLA-A- and HLA-B-compatible platelet transfusions were successful in boosting platelet levels with 82 of the patients. This study concerns the remaining six HLA-immunized patients who were refractory to HLA-A- and HLA-B-compatible platelet transfusions. The response to the platelet transfusions was assessed by calculating both 1- and 24-hour posttransfusion CCIs for each transfusion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The average CCI(1 hour) and CCI(24 hours) in all patients were 20.0 and 12.8 for HLA-A-, HLA-B-, and HLA-C-compatible transfusions and were 1.4 and 1.2 for HLA-A- and HLA-B-compatible but HLA-C-incompatible transfusions, respectively (p < 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings clearly indicate that matching of the HLA-C antigens is also required in some alloimmunized patients to obtain the effectiveness of platelet transfusions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Tissue Typing Laboratory, Nagano Red Cross Blood Center, Japan. stsaito@poplar.ocn.ne.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Seshimo</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Yuichiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Setsuo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Miki</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transfusion</MedlineTA><NlmUniqueID>0417360</NlmUniqueID><ISSNLinking>0041-1132</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015236">HLA-C Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007518">Isoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001787" MajorTopicYN="N">Blood Group Incompatibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015236" MajorTopicYN="N">HLA-C Antigens</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006648" MajorTopicYN="Y">Histocompatibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007518" MajorTopicYN="N">Isoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017713" MajorTopicYN="Y">Platelet Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11961234</ArticleId><ArticleId IdType="doi">10.1046/j.1537-2995.2002.00051.x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Fukushima, Hirofumi" sort="Fukushima, Hirofumi" uniqKey="Fukushima H" first="Hirofumi" last="Fukushima">Hirofumi Fukushima</name><name sortKey="Ito, Toshihiro" sort="Ito, Toshihiro" uniqKey="Ito T" first="Toshihiro" last="Ito">Toshihiro Ito</name><name sortKey="Maeda, Hiroo" sort="Maeda, Hiroo" uniqKey="Maeda H" first="Hiroo" last="Maeda">Hiroo Maeda</name><name sortKey="Miki, Jun" sort="Miki, Jun" uniqKey="Miki J" first="Jun" last="Miki">Jun Miki</name><name sortKey="Nomura, Setsuo" sort="Nomura, Setsuo" uniqKey="Nomura S" first="Setsuo" last="Nomura">Setsuo Nomura</name><name sortKey="Ota, Masao" sort="Ota, Masao" uniqKey="Ota M" first="Masao" last="Ota">Masao Ota</name><name sortKey="Ota, Satoshi" sort="Ota, Satoshi" uniqKey="Ota S" first="Satoshi" last="Ota">Satoshi Ota</name><name sortKey="Seshimo, Hideyuki" sort="Seshimo, Hideyuki" uniqKey="Seshimo H" first="Hideyuki" last="Seshimo">Hideyuki Seshimo</name><name sortKey="Yamazaki, Yuichiro" sort="Yamazaki, Yuichiro" uniqKey="Yamazaki Y" first="Yuichiro" last="Yamazaki">Yuichiro Yamazaki</name></noCountry><country name="Japon"><noRegion><name sortKey="Saito, Satoshi" sort="Saito, Satoshi" uniqKey="Saito S" first="Satoshi" last="Saito">Satoshi Saito</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004543 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004543 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11961234
|texte= Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11961234" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |